These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 30473528)
1. In vitro antibacterial susceptibility of different brands of oral levofloxacin 250 mg tablet against Staphylococcus aureus and Escherichia coli. Bano R; Arsalan A Pak J Pharm Sci; 2018 Nov; 31(6):2529-2535. PubMed ID: 30473528 [TBL] [Abstract][Full Text] [Related]
2. Antibacterial Properties of Tebipenem Pivoxil Tablet, a New Oral Carbapenem Preparation against a Variety of Pathogenic Bacteria in Vitro and in Vivo. Yao Q; Wang J; Cui T; Yang Z; Su M; Zhao P; Yan H; Zhan Y; Yang H Molecules; 2016 Jan; 21(1):62. PubMed ID: 26751436 [TBL] [Abstract][Full Text] [Related]
3. Ex vivo antibacterial activity of levofloxacin against Escherichia coli and its pharmacokinetic profile following intravenous and oral administrations in broilers. Lee HK; DeVito V; Vercelli C; Tramuta C; Nebbia P; Re G; Kovalenko K; Giorgi M Res Vet Sci; 2017 Jun; 112():26-33. PubMed ID: 28113087 [TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model. Odenholt I; Cars O J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293 [TBL] [Abstract][Full Text] [Related]
5. McCurdy S; Lawrence L; Quintas M; Woosley L; Flamm R; Tseng C; Cammarata S Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630189 [TBL] [Abstract][Full Text] [Related]
6. In vitro equivalence of generic and branded amoxicillin tablet by microbiological assay method. Avianto P; Mahfudz ; Suharjono ; Isnaeni ; Alderman CP J Basic Clin Physiol Pharmacol; 2020 Jan; 30(6):. PubMed ID: 31939272 [TBL] [Abstract][Full Text] [Related]
7. Bioequivalence and in vitro antimicrobial activity between generic and brand-name levofloxacin. Sun HY; Liao HW; Sheng MH; Tai HM; Kuo CH; Sheng WH Diagn Microbiol Infect Dis; 2016 Jul; 85(3):347-351. PubMed ID: 27181716 [TBL] [Abstract][Full Text] [Related]
8. [Determination of in vitro susceptibilities of Brucella spp. strains against 11 different antibacterial gents isolated from blood cultures]. Keşli R; Bilgin H; Yılmaz H Mikrobiyol Bul; 2017 Jul; 51(3):260-268. PubMed ID: 28929962 [TBL] [Abstract][Full Text] [Related]
9. Comparison of the bactericidal activity of moxifloxacin and levofloxacin against Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli and Klebsiella pneumoniae. Lemmen SW; Häfner H; Klik S; Lütticken R; Zolldann D Chemotherapy; 2003 May; 49(1-2):33-5. PubMed ID: 12714807 [TBL] [Abstract][Full Text] [Related]
10. Comparison of Clinical Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing guidelines for the interpretation of antibiotic susceptibility at a University teaching hospital in Nairobi, Kenya: a cross-sectional study. Kassim A; Omuse G; Premji Z; Revathi G Ann Clin Microbiol Antimicrob; 2016 Apr; 15():21. PubMed ID: 27068515 [TBL] [Abstract][Full Text] [Related]
12. Antimicrobial susceptibility among important pathogens collected as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) in Spain, 2004-2014. Marco F; Dowzicky MJ J Glob Antimicrob Resist; 2016 Sep; 6():50-56. PubMed ID: 27530839 [TBL] [Abstract][Full Text] [Related]
13. Synthesis and evaluation of new quinazolin-4(3H)-one derivatives as potent antibacterial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis. Gatadi S; Gour J; Shukla M; Kaul G; Dasgupta A; Madhavi YV; Chopra S; Nanduri S Eur J Med Chem; 2019 Aug; 175():287-308. PubMed ID: 31096152 [TBL] [Abstract][Full Text] [Related]
14. Changes in minimum inhibitory concentration of levofloxacin for Escherichia coli strains isolated from urine samples in mainland China, 2004 to 2014. Li Y; Zheng B; Xue F; Zhu SN; Lyu Y J Microbiol Immunol Infect; 2017 Jun; 50(3):390-392. PubMed ID: 27593098 [TBL] [Abstract][Full Text] [Related]
15. Phenotypic and genotypic characterisation of multiple antibiotic-resistant Staphylococcus aureus exposed to subinhibitory levels of oxacillin and levofloxacin. Jo A; Ahn J BMC Microbiol; 2016 Jul; 16(1):170. PubMed ID: 27473500 [TBL] [Abstract][Full Text] [Related]
16. [In vitro activity of sitafloxacin against clinical isolates in 2012]. Amano A; Matsuzaki K; Kishi N; Koyama H; Hasegawa M; Ikeda F; Matsumoto T; Yamaguchi H; Okutani Y Jpn J Antibiot; 2013 Dec; 66(6):311-30. PubMed ID: 24649797 [TBL] [Abstract][Full Text] [Related]
17. Antibacterial effects of moxifloxacin and levofloxacin simulating epithelial lining fluid concentrations against community-acquired methicillin-resistant Staphylococcus aureus. Lee SY; Fan HW; Sutherland C; DeRyke AC; Nicolau DP Drugs R D; 2007; 8(2):69-77. PubMed ID: 17324004 [TBL] [Abstract][Full Text] [Related]
18. In vitro susceptibility of clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) to manufactured generic drugs compared with the brand vancomycin. Fujimura S; Watanabe A; Fuse K; Kikuchi T; Gomi K; Tokue Y Int J Antimicrob Agents; 2008 Apr; 31(4):391-2. PubMed ID: 18308516 [No Abstract] [Full Text] [Related]
19. In vitro bactericidal activity of cefepime and cefpirome against clinical isolates at Karachi. Arsalan A; Naqvi SB; Ali SA; Ahmed S; Shakeel O Pak J Pharm Sci; 2015 May; 28(3):841-7. PubMed ID: 26004702 [TBL] [Abstract][Full Text] [Related]
20. [Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from class B hospitals in China during 2013 and 2014]. Sun H; Chen L; Chen X; Jia X; Li N; Liu W; Tong H; Xiang R; Zhang F; Zhao H; Zhang J; Xu Y Zhonghua Jie He He Hu Xi Za Zhi; 2016 Jan; 39(1):30-7. PubMed ID: 26792053 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]